8E: Immune Engineering SIG 2

Date: Saturday, March 28, 2026
Time: 10:30 AM to 12:30 PM

Room: Hanover CDE

Description

Over the past decade the focus of many bioengineers and clinicians has been shifting towards "immune engineering" approaches that include but are not limited to engineered biomaterials for vaccines, immunotherapy (immune-modulation), cell and gene therapy, immune microenvironment engineering, and systems immunology. These research areas embrace a comprehensive list of translational immunology-associated problems including chronic infections, autoimmune diseases, aggressive cancers, allergies, etc. The purpose of the Immune Engineering SIG is to bring together emerging ideas and provide a venue for professional interaction to a large number of academic and industrial research groups and scientists working in these areas.

Moderators:

Joshua Doloff, Ph.D
Johns Hopkins University

Abhinav Acharya
Associate Chair for Research, Department of Biomedical Engineering
Case Western Reserve University

10:30 AM. 429. Programmable microparticles rewire CAR signaling to enable super-physiological expansion of human T cells in vitro.Xiao Huang1 1Drexel University
10:45 AM. 430. Adhesive Nonfibrotic Interfaces: Spatial Transcriptomic Atlas and Mechanistic Insight.Bastien Aymon1, Jiayi Liu1, Layan AlSharif1, Jianzhu Chen, Dr.1, Xuanhe Zhao, Dr.1 1Massachusetts Institute of Technology
11:15 AM. 432. Placental-Mimicry Macroencapsulated Cell Therapy Delays Bystander Cell Rejection in Xenogeneic Model.Shivani Hiremath, MS1, Chishiba Chilimba, MS1, Aditya Misra, B.S.E.1, Jessica Weaver, Ph.D.1 1Arizona State University
11:30 AM 433. Systemic mRNA vaccine priming and pulmonary circRNA vaccine booster elicited robust lung mucosal immunity for the prevention of SARS-CoV-2 infection and the immunotherapy of lung metastatic melanoma.Guizhi Zhu, PhD1 1University of Michigan
11:45. 434. Harnessing Nanoscale Oligonucleotide Presentation to Overcome Tumor Immunosuppression.Michelle Teplensky, PhD1 1Boston University
12:00 PM. 435. Harnessing DNA-based vaccines to generate lung-resident immunity.Siyi Zheng1, Meredith Davis1, Michael Vannini1, Joseph Mizgerd1, Michelle Teplensky, PhD1 1Boston University
12:15 PM. 436. Cancer-inspired microparticles drive differential modulation of bone-marrow-derived dendritic cells and potentiate diverse polarization in T cells.Krishna Gaddam1, Allen B Tu1, Reuben Abraham1, Jamal Lewis, Ph.D.1 1University of florida

Description

10:30 AM. 429. Programmable microparticles rewire CAR signaling to enable super-physiological expansion of human T cells in vitro.Xiao Huang1 1Drexel University

10:45 AM. 430. Adhesive Nonfibrotic Interfaces: Spatial Transcriptomic Atlas and Mechanistic Insight.Bastien Aymon1, Jiayi Liu1, Layan AlSharif1, Jianzhu Chen, Dr.1, Xuanhe Zhao, Dr.1 1Massachusetts Institute of Technology

11:15 AM. 432. Placental-Mimicry Macroencapsulated Cell Therapy Delays Bystander Cell Rejection in Xenogeneic Model.Shivani Hiremath, MS1, Chishiba Chilimba, MS1, Aditya Misra, B.S.E.1, Jessica Weaver, Ph.D.1 1Arizona State University

11:30 AM 433. Systemic mRNA vaccine priming and pulmonary circRNA vaccine booster elicited robust lung mucosal immunity for the prevention of SARS-CoV-2 infection and the immunotherapy of lung metastatic melanoma.Guizhi Zhu, PhD1 1University of Michigan

11:45. 434. Harnessing Nanoscale Oligonucleotide Presentation to Overcome Tumor Immunosuppression.Michelle Teplensky, PhD1 1Boston University

12:00 PM. 435. Harnessing DNA-based vaccines to generate lung-resident immunity.Siyi Zheng1, Meredith Davis1, Michael Vannini1, Joseph Mizgerd1, Michelle Teplensky, PhD1 1Boston University

12:15 PM. 436. Cancer-inspired microparticles drive differential modulation of bone-marrow-derived dendritic cells and potentiate diverse polarization in T cells.Krishna Gaddam1, Allen B Tu1, Reuben Abraham1, Jamal Lewis, Ph.D.1 1University of florida